Form 4: Oramed CEO Kidron Granted 167,005 RSUs

Oramed Pharmaceuticals Inc. CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units, which will vest quarterly starting April 1, 2026.

Summary

• Nadav Kidron, President and CEO of Oramed Pharmaceuticals Inc. (ORMP), acquired 167,005 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was March 17, 2026.
• The RSUs were granted at a price of $0 per unit.
• Following this transaction, Nadav Kidron beneficially owns 3,422,243 shares of common stock.
• These RSUs will vest ratably in 8 quarterly installments, with the vesting period commencing on April 1, 2026.
• Each RSU represents the right to receive one share of Oramed Pharmaceuticals Inc. common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment from the CEO and aligns his incentives with the company's long-term success, which is generally favorable for investors.

Positives

• The grant of Restricted Stock Units aligns management's interests with long-term shareholder value through equity ownership.
• The vesting schedule over 8 quarterly installments encourages continued leadership and performance from the CEO.

Negatives

• The future conversion of RSUs into common stock will result in a minor dilution of existing shareholder equity.

Risks

• Future dilution of common stock upon the vesting and conversion of the 167,005 Restricted Stock Units.

Future Outlook

The grant of Restricted Stock Units indicates a future increase in the outstanding share count as these units vest and convert into common stock, beginning April 1, 2026, and continuing over 8 quarterly installments.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to a CEO is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to incentivize long-term performance and align management interests with shareholder returns. This type of equity award is common across companies of similar size and development stage as Oramed Pharmaceuticals.

Comparison to Industry Standards

• The grant of 167,005 RSUs to the CEO is within the typical range for executive equity compensation in the pharmaceutical sector, comparable to grants observed at companies like BioNTech SE or Moderna Inc. for their senior executives, adjusted for company size and market capitalization.
• The 8-quarter ratable vesting schedule is a common mechanism to ensure retention and sustained performance, similar to practices at peer companies such as Novavax, Inc. or Vaxart, Inc., which often use multi-year vesting periods for executive equity awards.

Stakeholder Impact

• Shareholders: Potential minor dilution upon RSU conversion, but also increased alignment of CEO's interests with long-term share price performance.
• Employees: May signal stability in executive leadership.

Next Steps

• The 167,005 Restricted Stock Units will begin vesting ratably in 8 quarterly installments starting April 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not provide new material information that would significantly alter the investment thesis for Oramed Pharmaceuticals Inc. While the grant aligns management incentives, it is a standard event and not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

Oramed Pharmaceuticals, ORMP, Nadav Kidron, Restricted Stock Units, RSU, Insider Transaction, Form 4, Executive Compensation, Equity Grant, Beneficial Ownership